In the international market, the price of ponatinib varies significantly due to factors such as drug specifications, procurement channels, and exchange rate fluctuations. Patients typically obtain the drug through overseas medical institutions or pharmacies, incurring relatively high costs.
Laos Daewoo version: 15 mg * 30 tablets per box, approximately $75 per box.
Laos Daewoo version: 45 mg * 30 tablets per box, approximately $197 per box.
Note: The above prices are for reference only.
Drug Interactions of Ponatinib
Interactions with CYP3A Inhibitors
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) significantly increase ponatinib plasma concentrations, raising the risk of adverse reactions.
Recommendation: Avoid concomitant use. If co-administration is unavoidable, reduce the ponatinib dose per the prescribing information and resume the original dose 3–5 half-lives after discontinuing the inhibitor.
Interactions with CYP3A Inducers
Strong CYP3A inducers (e.g., rifampicin, carbamazepine, phenytoin) decrease ponatinib plasma concentrations, potentially leading to treatment failure.
Recommendation: Avoid concomitant use. If unavoidable, closely monitor efficacy and consider alternative agents with no or weak CYP3A-inducing effects.
Interactions with Other Drugs or Food
Acid-suppressing agents: Concomitant use with proton pump inhibitors (e.g., lansoprazole) may slightly reduce ponatinib exposure, but the clinical significance is unclear. Monitor efficacy.
Special food: Avoid grapefruit or grapefruit juice during treatment, as they may inhibit CYP3A and increase drug exposure and toxicity risk.
Pharmacokinetics of Ponatinib
Absorption and Distribution
Absorption: Peak plasma concentration is reached approximately 6 hours after oral administration. Food does not affect absorption; thus, ponatinib may be taken with or without food.
Bioavailability: Absolute bioavailability is not yet established.
Protein binding: Extremely high (>99%). Ponatinib binds extensively to plasma proteins, but displacement interactions with other highly protein-bound drugs (e.g., warfarin) are not clinically significant.
Volume of distribution: Mean apparent volume of distribution is large (approximately 1,223 L), indicating extensive tissue distribution.
Metabolism and Excretion
Metabolic pathways: Primarily metabolized in the liver by CYP3A4; CYP2C8, CYP2D6, and CYP3A5 also contribute to partial metabolism. Esterases/amidase are additionally involved.
Excretion pathways: Following oral administration of radiolabeled drug, approximately 87% is excreted in feces and 5% in urine.
Half-life: Mean terminal elimination half-life is approximately 24 hours, supporting once-daily dosing.
